First Eagle Investment Management LLC lifted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 334.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 49,229 shares of the biopharmaceutical company’s stock after purchasing an additional 37,900 shares during the quarter. First Eagle Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $3,138,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. First Trust Advisors LP lifted its position in Bristol-Myers Squibb by 10.7% in the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after buying an additional 41,892 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in Bristol-Myers Squibb by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after buying an additional 8,813 shares during the last quarter. Israel Discount Bank of New York lifted its position in Bristol-Myers Squibb by 31.8% in the second quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock worth $586,000 after buying an additional 2,540 shares during the last quarter. Dividend Assets Capital LLC bought a new stake in Bristol-Myers Squibb in the second quarter worth $737,000. Finally, Ffcm LLC lifted its position in Bristol-Myers Squibb by 6.4% in the second quarter. Ffcm LLC now owns 49,133 shares of the biopharmaceutical company’s stock worth $2,738,000 after buying an additional 2,958 shares during the last quarter. 69.67% of the stock is owned by hedge funds and other institutional investors.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.81 on Friday. Bristol-Myers Squibb Co has a 52-week low of $46.01 and a 52-week high of $66.10. The firm has a market capitalization of $102,800.00, a price-to-earnings ratio of 24.73, a PEG ratio of 2.22 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the business posted $0.77 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. equities research analysts predict that Bristol-Myers Squibb Co will post 2.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.99%.

BMY has been the subject of a number of analyst reports. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research report on Wednesday, November 1st. Barclays raised their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 26th. Finally, Leerink Swann raised their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $65.05.

In other news, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “First Eagle Investment Management LLC Acquires 37,900 Shares of Bristol-Myers Squibb Co (BMY)” was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.watchlistnews.com/first-eagle-investment-management-llc-acquires-37900-shares-of-bristol-myers-squibb-co-bmy/1805321.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.